![](https://www.l-ten.org/wp-content/uploads/2023/11/LTEN-Member-News.png)
Paris, May 30, 2024. Sanofi announced today the completion of its acquisition of Inhibrx, Inc. (“Inhibrx”). The acquisition adds SAR447537 (formerly INBRX-101) to Sanofi’s rare disease pipeline, underscoring the company’s commitment to pursuing differentiated and…